Secures $400M senior secured credit facility from OrbiMed

What did Intellia Therapeutics, Inc. announce?

Intellia Therapeutics obtained a $400 million senior secured credit facility with an initial $75 million funded at closing.

Key details

• The credit facility provides up to $400 million, with $75 million drawn on the closing date of September 4, 2026.
• Additional draws are tied to milestones, including FDA approval of lonvoguran ziclumeran and revenue targets.
• The facility matures on September 4, 2031, with an interest rate of SOFR + 6.15%.
• All obligations are secured by substantially all company assets, including intellectual property.

Why it matters

This 8-K reports a financing at Intellia Therapeutics, Inc.. The likely share-price reaction reads as positive.

More from Intellia Therapeutics, Inc.

• 8-K

  Sep 8, 2026
  FDA accepts BLA for Lonvo-z with Priority Review for HAE

All Intellia Therapeutics, Inc. SEC filings →